-
Engineering News reports that Science and Technology Minister Naledi Pandor announced that South Africa will set up a R1.6-billion plant to manufacture active pharmaceutical ingredients (AIPs) for antiretroviral medicines (ARVs) in a joint venture with S Full Article at AllAfrica.com
-
The minister of Science and Technology, Naledi Pandor has awarded 60 new Research Chairs under the South African Research Chairs Initiative (SARChI), a flagship initiative of government to attract and retain excellence in research and innovation in the S Full Article at AllAfrica.com
-
Pretoria — Science and Technology Minister Naledi Pandor has announced that a total of 60 new Research Chairs will be awarded to various institutions of higher learning across South Africa during the 2011/12 and 2013/14 Medium Term Expenditure Framework. Full Article at AllAfrica.com
-
2012-02-13 22:34 Cape Town - As South Africa waits for a decision on the country that will win the bid to host the Square Kilometre Array (SKA) telescope, engineers are confident that the MeerKAT will go ahead. "MeerKAT gets built, whether we win the SKA Full Article at News24
-
Swiss drug manufacturer Lonza has allied with the South African government on a new, $210 million plant to produce antiretroviral APIs. The venture, dubbed Ketlaphela, is aimed at reducing drugmakers' imports of ingredients for HIV-fighting drugs, beginn Full Article at FiercePharma
-
The joint announcement by Ministers Naledi Pandor and Rob Davies that government will establish a pharmaceutical manufacturing plant left a few questions unanswered during today's press conference. It is common cause that South Africa has a R25-billion m Full Article at AllAfrica.com
-
THE STATE is to invest R1 billion in the construction of a pharmaceuticals plant, which is aiming to produce antiretroviral (ARV) ingredients by 2016. The plant, a joint venture between Swiss pharmaceutical company Lonza, the Industrial Development Corpo Full Article at Independent Online (South Africa)
-
CAPE TOWN - A R1.6bn joint venture between the government and leading biochemicals company, Lonza, is expected to significantly cut South Africa’s dependence on imported drugs... Full Article at Moneyweb
-
New plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant have been unveiled by South Africa. This plant will be developed in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs. The plant will prod Full Article at Medindia Health News
-
Cape Town — The South African government has entered into a massive partnership with a leading global pharmaceutical company to manufacture the ingredients of Anti-Retroviral (ARV) drugs locally. South Africa is the largest consumer of ARVs in the world Full Article at AllAfrica.com
